Vitafoods Insights is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Que Sera Sera: Future Applications for Probiotics

1 15
Que sera sera is the title of a song by Doris Day from 1956. In this song, the mother tells her daughter that ‘Whatever will be, will be, The future's not ours to see’. The mother is correct; it is impossible to predict the future. Still, it would be helpful to get at least some idea of what the future could hold, and that includes the future of probiotics.

Current applications of probiotics focus on prevention and/or treatment of gastrointestinal diseases and immune mediated diseases. In all clinical trials with probiotics which have been conducted to date (and listed at ), a total of 713 different diseases and conditions have been studied. The top 10 of conditions investigated most is dominated by gastrointestinal diseases and digestive system diseases. From these clinical studies—most of them performed on patients—the beneficial effects of probiotics for a number of gastrointestinal diseases, including diarrhoea, have been demonstrated. It is unfortunate that due to regulatory frameworks, this evidence cannot be used to substantiate health claims for probiotics in this domain. To a certain degree this also holds true for immune mediated disease. lists 86 studies on probiotics that are not recruiting yet, or are active but not recruiting yet. These include clinical trials on communicable disease, endocrine diseases, mental disorders and psychotic disorders. With an aging population, and with a growing body of evidence for the importance of the gut-brain axis, it could be expected that there also would be increased attention for the application of probiotics in neurodegenerative diseases. The number of clinical studies on potential beneficial effects of probiotics in diseases such as Parkinson and Alzheimer however is disappointingly low, with just 5 studies registered at That amounts to 0.1 percent of all clinical studies for this domain. It should be added that 2 of those studies address the problem of constipation in Parkinson’s, and not the primary disease process.

The phrase ‘Que sera sera, whatever will be will be’ has a flavor of theological predestination. While it is impossible to predict the future, the future can be shaped. Investing time and effort in setting up appropriately designed and powered clinical studies with relevant endpoints can form the basis for future therapies of neurodegenerative diseases. While reversion of the disease process may be impossible, halting or slowing down progression of the disease would already be a major step forward.

The song Que sera sera was first used in the Hitchcock movie called The Man that Knew Too Much. For future applications of probiotics, we still know too little, so let the investigations begin.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.